The United States Food and Drug Agency (FDA) granted this Saturday the emergency authorization to Regeneron, the drug against COVID-19 that the American president received in October, Donald Trump, to treat the disease. The authorization limits the use of the drug to people over 12 years old that they have given positive for coronavirus and be in risk of developing a severe case of the disease, including those 65 and older, as well as those with certain chronic medical conditions.
This is because the treatment, based on a cocktail of monoclonal antibodies casirivimab and imdevimab, has shown that its early application improves the condition of patients. Instead of waiting for the body to develop its own protective immune response, the drug mimics the body’s natural defenses, thus the doctors hope to avoid many hospitalizations. “It was shown that almost irivimab and imdevimab, administered together, reduce hospitalization related to COVID-19 or emergency room visits in patients at high risk of disease progression within 28 days of treatment compared to placebo“, explains the FDA in a statement.
Bill Gates defined it as the “most effective” treatment
The treatment was defined by Bill Gates, founder of Microsoft, as the best drug to fight COVID-19. “Monoclonal antibody treatments like the one President Donald Trump received may be the most effective approach to treating coronavirus infections,” Gates said when Trump was receiving the regeneron.
Shortly after confirming her contagion in early October, Trump received an 8 gram dose of this Regeneron treatment, even though its use was not cleared by the FDA. After overcoming the disease, the president affirmed through videos and social networks that this treatment was the main responsible for his improvement, defining it not as “therapy”, but as a “care”.
Free access to the drug
When leaving the hospital, Trump promised that he would guarantee free access to this drug. The company has received more than 500 million dollars from the US federal government (approximately 421.7 million euros) and the first 300,000 doses will be free in the United States, although Americans could pay depending on their insurance to have it applied, since it must be used in a hospital.
According to company calculations, end of november they will have enough dose for 80,000 people and they will be able to treat 200,000 patients at the beginning of January already 300,000 at the end of the month, since they have reached an agreement with the Swiss company Roche for the production of the drug.
*The article has been translated based on the content of Source link by https://as.com/diarioas/2020/11/22/actualidad/1606034809_269374.html
. If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!
*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.
*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!